There is bad news for Glaxo and Xenoport as their experimental migraine drug has failed in a clinical trial.
The drug, known as gabapentin enacarbil was being tested against a placebo in people who suffered frequent migraines but showed no benefit when it came to reducing the painful episodes.
The trial lasted for a total of 30 weeks and featured 526 migraine patients, randomly assigned to receive either the drug or a placebo.
“We are disappointed by the results of GSK1838262 in this clinical setting,” Atul Pande of GSK’s Neurosciences Medicines Development Centre said in a statement.
“We remain committed to working with our partners and regulatory authorities to make this product candidate available to patients with unmet medical needs,” said XenoPort chief executive Ronald Barrett.
Share holders were quick to act upon news of the failed clinical trials, sending stock in both companies down in early morning trading.
Source: GSK Pharma
